Все публикации

0:15:04

Physician Coaching and Embracing QI

0:02:05

Perspectives in mCRPC in 2024

0:02:03

Metastatic Prostate Cancer: Can Urologists Work Alongside Medical Oncologists in Advanced Disease?

0:05:00

ESMO Updates - EMBARK Study & PSMAfore Trial

0:11:08

Outpatient Exercise, Nutrition, and Psychologic Support and Pre-Rehabilitation for Urologic Cancer

0:08:55

Testosterone Update on Oral Products

0:15:32

Case Discussion: Early Detection of Prostate Cancer 2023

0:11:33

Recurrent UTIs: Ask the Guideline

0:11:53

Early Detection of Prostate Cancer: Navigating the Challenges

0:16:22

PSA Screening in 2023

0:06:24

mCRPC - Results from the Triton 3 Study

0:08:35

Garnick - Review of the New Standard in Treatment and Global Issues

0:14:36

DECIPHER: Predicting Prognosis and Assisting Treatment Decisions for Prostate Cancer

0:16:42

Neoadjuvant Therapy for MIBC in the Genomic Era

0:12:30

RADAR 6 & 7 – Detection of Advanced Prostate Cancer Recurrence

0:16:39

Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved Outcomes

0:10:44

Earlier Use of Immune Checkpoint Inhibitors to Adjuvant and Non Muscle Invasive Bladder Cancer

0:17:36

Forward Progress in Molecular Markers for Prostate Cancer

0:13:06

Selecting Candidates for Focal Therapy

0:16:26

Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

0:21:10

Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and New

0:15:16

Male Mortality & Men’s Health Issues: Barriers, Testosterone, PDE5 Therapy, and GLP1 Agonist Therapy

0:21:36

Resident Training: Can We Be Too Hard?

0:06:47

Patient's Journey: Experience with mCRPC and the Lutetium (Pluvicto) Shortage